Abstract
In 20 depressed patients treated with nortriptyline (NT) there was a significant relationship between the plasma concentration of NT and the debrisoquine metabolic ratio (rs = 0.77; P less than 0.01). (The debrisoquine test was performed after stopping NT treatment). This is in agreement with the hypothesis that the hydroxylations of NT and debrisoquine are mediated by similar enzymatic mechanisms. In contrast there was no significant relationship between the debrisoquine metabolic ratio and the plasma concentrations of the active metabolite 10-hydroxy-nortriptyline. In 11 of the patients the debrisoquine metabolic ratio was significantly higher during than after NT treatment. This may be due to an inhibition of the debrisoquine hydroxylation by NT.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bertilsson L., Aberg-Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol. 1983 Mar;15(3):388–390. doi: 10.1111/j.1365-2125.1983.tb01518.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bertilsson L., Mellström B., Sjöqvist F. Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. Life Sci. 1979 Oct 8;25(15):1285–1292. doi: 10.1016/0024-3205(79)90393-x. [DOI] [PubMed] [Google Scholar]
- Borgå O., Garle M. A gas chromatographic method for the quantitative determination of notriptyline and some of its metabolites in human plasma and urine. J Chromatogr. 1972 May 31;68(1):77–88. doi: 10.1016/s0021-9673(00)88765-8. [DOI] [PubMed] [Google Scholar]
- Dawling S., Lynn K., Rosser R., Braithwaite R. Nortriptyline metabolism in chronic renal failure: metabolite elimination. Clin Pharmacol Ther. 1982 Sep;32(3):322–329. doi: 10.1038/clpt.1982.167. [DOI] [PubMed] [Google Scholar]
- Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
- Mellström B., Bertilsson L., Säwe J., Schulz H. U., Sjöqvist F. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther. 1981 Aug;30(2):189–193. doi: 10.1038/clpt.1981.147. [DOI] [PubMed] [Google Scholar]
- Silas J. H., Tucker G. T., Smith A. J., Fieller N. R. Accumulation of debrisoquine by platelets in vivo: a model of events at the peripheral adrenergic neurone. Br J Clin Pharmacol. 1980 Apr;9(4):419–425. doi: 10.1111/j.1365-2125.1980.tb01071.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sloan T. P., Lancaster R., Shah R. R., Idle J. R., Smith R. L. Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol. 1983 Apr;15(4):443–450. doi: 10.1111/j.1365-2125.1983.tb01528.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Woolhouse N. M., Adjepon-Yamoah K. K., Mellström B., Hedman A., Bertilsson L., Sjöqvist F. Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects. Clin Pharmacol Ther. 1984 Sep;36(3):374–378. doi: 10.1038/clpt.1984.190. [DOI] [PubMed] [Google Scholar]
- Wägner A., Ekqvist B., Bertilsson L., Sjöqvist F. Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors. Life Sci. 1984 Sep 24;35(13):1379–1383. doi: 10.1016/0024-3205(84)90395-3. [DOI] [PubMed] [Google Scholar]
- von Bahr C., Birgersson C., Blanck A., Göransson M., Mellström B., Nilsell K. Correlation between nortriptyline and debrisoquine hydroxylation in the human liver. Life Sci. 1983 Aug 15;33(7):631–636. doi: 10.1016/0024-3205(83)90251-5. [DOI] [PubMed] [Google Scholar]